In this article, we will discuss Ceritinib (Dosage Overview). So, let’s get started.
Ceritinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Select patients for treatment of metastatic NSCLC with Ceritinib based on the presence of ALK positivity in tumor specimens.
The recommended dosage of Ceritinib is 450 mg orally once daily with food until disease progression or unacceptable toxicity.
If a dose of Ceritinib is missed, make up that dose unless the next dose is due within 12 hours.
If vomiting occurs during the course of treatment, do not administer an additional dose and continue with the next scheduled dose of Ceritinib.